Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

被引:60
|
作者
Ma, CX
Nair, S
Thomas, S
Mandrekar, SJ
Nikcevich, DA
Rowland, KM
Fitch, TR
Windschitl, HE
Hillman, SL
Schild, SE
Jett, JR
Obasaju, C
Adjei, AA
机构
[1] Mayo Clin & Mayo Fdn, Dept Oncol & Med, Div Med Oncol, Rochester, MN 55905 USA
[2] Duluth CCOP, Duluth, MN USA
[3] CentraCare Clin, St Cloud, MN USA
[4] Geisinger Med Ctr, Danville, PA 17822 USA
[5] Illinois Oncol Res Assoc, CCOP, Peoria, IL USA
[6] Carle Canc Ctr, CCOP, Urbana, IL USA
[7] Scottsdale CCOP, Scottsdale, AZ USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
D O I
10.1200/JCO.2005.13.953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naive patients with non-small-cell lung cancer. Patients and Methods Patients were randomly assigned to three schedules of pemetrexed 500 mg/m(2) plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. Results One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P =.19; grade 4 events: 39% v 48%, respectively; P =.30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. Conclusion Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated.
引用
收藏
页码:5929 / 5937
页数:9
相关论文
共 50 条
  • [11] Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin:: A multicenter phase II trial
    Manegold, C
    Gatzemeier, U
    von Pawel, J
    Pirker, R
    Malayeri, R
    Blatter, J
    Krejcy, K
    ANNALS OF ONCOLOGY, 2000, 11 (04) : 435 - 440
  • [12] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial
    Stathopoulos, GP
    Dimitroulis, J
    Antoniou, D
    Katis, C
    Tsavdaridis, D
    Armenaki, O
    Marosis, C
    Michalopoulou, P
    Grigoratou, T
    Stathopoulos, J
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1106 - 1111
  • [13] A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
    Masters, Gregory A.
    Argiris, Athanassios E.
    Hahn, Elizabeth A.
    Beck, J. Thaddeus
    Rausch, P. Gregory
    Ye, Zhishen
    Monberg, Matthew J.
    Bloss, Leslie P.
    Curiel, Rafael E.
    Obasaju, Coleman K.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (01) : 19 - 24
  • [14] Gemcitabine as second-line treatment for advanced non-small-cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, G
    Selvaggi, G
    Novello, S
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Rossi, A
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2081 - 2085
  • [15] Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer
    Schneider, Bryan J.
    Kalemkerian, Gregory P.
    Gadgeel, Shirish M.
    Valdivieso, Manuel
    Hackstock, Deborah M.
    Chen, Wei
    Heilbrun, Lance K.
    Ruckdeschel, John C.
    Wozniak, Antoinette J.
    CLINICAL LUNG CANCER, 2017, 18 (03) : 299 - 302
  • [16] A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non-Small-Cell Lung Cancer
    Pallis, Athanasios G.
    Voutsina, Alexandra
    Kentepozidis, Nikolaos
    Giassas, Stylianos
    Papakotoulas, Pavlos
    Agelaki, Sofia
    Tryfonidis, Kostas
    Kotsakis, Athanasios
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Georgoulias, Vassilis
    CLINICAL LUNG CANCER, 2012, 13 (02) : 129 - 135
  • [17] Vinorelbine/gemcitabine in advanced non-small-cell lung cancer: an AASLC phase II trial
    Krajnik, G
    Malayeri, R
    Thaler, J
    Mohn-Staudner, A
    Greil, R
    Schmeikal, S
    Marhold, F
    Deutsch, J
    Preiss, P
    Zoechbauer-Mueller, S
    Huber, H
    Pirker, R
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 647 - 649
  • [18] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    McCleod, M
    Treat, J
    Christiansen, NP
    Mintzer, DM
    Bonomi, P
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [19] Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
    Lilenbaum, RC
    Chen, CS
    Chidiac, T
    Schwarzenberger, PO
    Thant, M
    Versola, N
    Lane, SR
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 97 - 101
  • [20] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos M.
    Dakhil, Shaker R.
    Lyss, Alan P.
    Loesch, David M.
    Waterhouse, David M.
    Bromund, Jane L.
    Chen, Ruqin
    Hristova-Kazmierski, Maria
    Treat, Joseph
    Obasaju, Coleman K.
    Marciniak, Martin
    Gill, John
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598